Water soluble fullerene formulations and methods of use thereof

1. A composition comprising at least one fullerene and at least one oxazoline polymer, wherein said fullerene is complexed with said oxazoline polymer, wherein said oxazoline polymer is a poly(2-alkyl-2-oxazoline), and wherein the composition comprises at least one pharmaceutically acceptable carrier or cosmetically acceptable carrier.

2. The composition of claim 1 , wherein said fullerene is pristine.

3. The composition of claim 1 , wherein the fullerene is C 60 .

4. The composition of claim 1 , wherein said oxazoline polymer is a homopolymer.

5. The composition of claim 1 , wherein said oxazoline polymer is a random or block copolymer.

6. The composition of claim 1 , wherein said oxazoline polymer comprises 2-ethyl-2-oxazoline.

7. The composition of claim 6 , wherein said oxazoline polymer is a homopolymer of 2-ethyl-2-oxazoline.

8. The composition of claim 6 , wherein said oxazoline polymer is a copolymer comprising 2-ethyl-2-oxazoline.

9. The composition of claim 1 , wherein the complexes comprise about 0.1% to about 5% fullerene.

10. The composition of claim 1 further comprising a cosmetically acceptable agent selected from the group consisting of sunscreens, anti-aging agents, chemotherapeutic agents, steroids, anti-inflammatory agents, exfoliating agents, lipid molecules, amino acids, vitamins, anti-irritation agents, anti-cellulite agents, anti-fungal agents, anti-bacterial agents, moisturizing agents, saccharides, emollients, antioxidants, anti-swelling agents, anesthetics, anti-viral agents, cosmetic agents, coloring agents, and fragrances.

11. A method for treating or inhibiting an oxidative stress associated disease or disorder in a subject in need thereof, said method comprising administering to said subject at least one composition of claim 1 .

12. The method of claim 11 , wherein said oxidative stress associated disease or disorder is selected from the group consisting of hypertension, heart failure, arthritis, cancer, neurodegenerative disorders, and cardiovascular diseases.

13. The method of claim 12 , wherein said neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Huntington's disease, Parkinson's disease, Lewy Body disease, amyotrophic lateral sclerosis, and prion disease.

14. The composition of claim 1 , wherein said fullerene and said oxazoline polymer form a charge-transfer complex.

15. The composition of claim 1 , wherein said complex of fullerene and the oxazoline polymer is a nanoparticle.

16. The composition of claim 1 , wherein said complex of fullerene and the oxazoline polymer has an average diameter of about 50 nm to about 500 nm.

17. The composition of claim 1 , wherein said complex of fullerene and the oxazoline polymer has an average diameter of about 100 nm to about 200 nm.